Maik W. Jornitz Becomes Chair-Elect of the Board of the Global Parenteral Drug Association

Fri Dec 7, 2007 9:49am EST

* Reuters is not responsible for the content in this press release.

GOETTINGEN, Germany & BETHESDA, Md.--(Business Wire)--After yesterday's meeting, the Board of Directors announced the
election of Maik W. Jornitz as Chair-Elect (Vice Chairman) of the
Board of the Parenteral Drug Association (PDA). The Group Vice
President, Marketing Filtration and Fermentation, at Sartorius Stedim
Biotech (FWB:SRT), has been an active member of the PDA for close to
15 years, holding multiple functions. Before becoming Chair-Elect, he
was Treasurer and Chair of the 2008 Annual Meeting as well as a Task
Forces member, including his direct involvement in Technical Report 26
on Liquid Sterilizing Filtration. The PDA is a key global
pharmaceutical association with over 10,000 members.

   "The PDA is the most prominent and effective platform of
scientific communication and discussion between members of the
biopharmaceutical and pharmaceutical industry, academia and regulatory
institutions," said Jornitz. "It is an honor to be part of PDA's vital
function in supporting regulators and the biopharmaceutical industry
as well as shaping the newest developments in this industry. I am very
happy to join this senior level and distinguished Board of Directors."
John Shabushnig was elected Chair of the PDA Board. Furthermore,
representatives of the pharmaceutical groups Genentech, Amgen, Pfizer,
Baxter and Eli Lilly, among others, belong to this Board.

   Maik W. Jornitz has been with Sartorius for over 20 years and is
an established filtration technology expert with a focus on
sterilizing filtration, process validation and integrity testing.
Jornitz authored and co-authored numerous scientific books, and
regularly publishes technical papers. He holds multiple patents for
integrity test methods and filter housing designs. Jornitz is a
faculty member of PDA's Training & Research Institute.

   Current image file:

   Maik W. Jornitz, Group Vice President Marketing & Product
Management Filtration/Fermentation Technologies at Sartorius Stedim
Biotech.

   http://www.sartorius-stedim.com/media/content/press/support/Jornit
z.jpg

   (Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)

   A profile of Sartorius Stedim Biotech

   Sartorius Stedim Biotech is a leading provider of cutting-edge
equipment and services for the development, quality assurance and
production processes of the biopharmaceutical industry. Its integrated
solutions covering fermentation, filtration, purification, fluid
management and lab technologies are supporting the biopharmaceutical
industry around the world to develop and produce drugs safely, timely
and economically. For next generation processes, Sartorius Stedim
Biotech focuses on single-use technologies and added-value services to
meet the rapidly changing technology requirements of the industry it
serves. Strongly rooted in the scientific community and closely allied
with customers and technology partners, the company is dedicated to
its philosophy of "Turning science into solutions."

   Headquartered in Aubagne, France, Sartorius Stedim Biotech is
listed on the Eurolist of Euronext Paris. With its own manufacturing
and sales companies in Europe, North America and Asia, Sartorius
Stedim Biotech enjoys a worldwide presence. Its key manufacturing and
R&D location is in Germany. The company employs over 2,200 people, and
in 2006 earned pro forma sales revenue of more than 360 million euros.

   This is a translation of the original German-language press
release. Sartorius shall not assume any liability for the correctness
of this translation. The original German press release is the legally
binding version. Furthermore, Sartorius reserves the right not to be
responsible for the topicality, correctness, completeness or quality
of the information provided. Liability claims regarding damage caused
by the use of any information provided, including any kind of
information which is incomplete or incorrect, will therefore be
rejected.

   http://www.sartorius-stedim.com

Sartorius Group Corporate Communications
Elke Schild +49-551/ 308-3684
fax: +49-551/ 308-3410
elke.schild@sartorius.com

Copyright Business Wire 2007
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.